Everpure, Fervo Energy, Charles River Laboratories And Other Big Stocks Moving Higher On Thursday

Why Is Arcturus Therapeutics Stock Gaining Thursday?

Arcturus Therapeutics (ARCT) surged over 6% after sharing positive Phase 2 interim data for its OTC deficiency drug, ARCT-810.

Citigroup Upgrades Arcturus Therapeutics to Buy, Raises Price Target to $20

Citigroup analyst Yigal Nochomovitz upgrades Arcturus Therapeutics (NASDAQ:ARCT) from Neutral to Buy and raises the price target from $8 to $20.

BTIG Maintains Buy on Arcturus Therapeutics, Lowers Price Target to $20

BTIG analyst Thomas Shrader maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and lowers the price target from $23 to $20.

Bally’s Corp. shares are trading higher after the company announced it has secured $560 million in financing to support development of the Bronx project and general corporate purposes.

8-K filing — Bally's Corp (BALY)

Filed: 2026-09-14 AccNo: 0001747079-26-000089 Size: 223 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Bally's CFO Mira Mircheva To Resign Effective On September 4, 2026; George Papanier Appointed As Interim Chief Financial Officer

Bally's Corporation (NYSE:BALY) announced today that Executive Vice President and Chief Financial Officer, Mira Mircheva, has notified the Company of her intent to resign her positions of Executive Vice President